1	Title: Mutation-specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of
2	Variants of Concern and the Identification of a Newly Emerging Variant with Spike
3	L452R Mutation
4	
5	Huanyu Wang ^{1,2} , Sophonie Jean ^{1,2} , Richard Eltringham ^{1,2} , John Madison ^{1,2} , Pamela
6	Snyder ² , Huolin Tu ² , Daniel M. Jones ^{2*} , Amy L. Leber ^{1,2,3*#}
7	
8	¹ Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital,
9	Columbus, OH
10	² Department of Pathology, The Ohio State University, Columbus, OH
11	³ Department of Pediatrics, The Ohio State University, Columbus, OH
12	
13	*Contributed equally
14	#Corresponding author: Amy L. Leber, Department of Pathology and Laboratory
15	Medicine, Nationwide Children's Hospital. Columbus, OH. Email:
16	Amy.Leber@nationwidechildrens.org, phone: 1-614-722-5445
17	
18	Running title: SARS-CoV-2 VOC Screening
19	Keywords: SARS-CoV-2, variant screening, newly emerging SARS-CoV-2 variant

20 Abstract

21	The emergence of more transmissible and/or more virulent SARS-CoV-2 variants of
22	concern (VOCs) has triggered intensive genomic surveillance, which is costly and
23	difficult to sustain operationally over the long-term. To address this problem, we
24	developed a set of four multiplex mutation-specific PCR-based assays with same-day
25	reporting that can detect five VOCs and three variants of interest (VOIs), as defined in
26	the March 2021 guidelines from the United States (US) Centers for Disease Control and
27	Prevention. The screening results were compared to the whole genome sequencing
28	(WGS) and showed 100% concordance for strain typing for B.1.1.7 (25) and P.1 (5)
29	variants using Spike (S) mutations N501Y, E484K and H69_V70del assays. The S
30	L450R assay, designed to detect the B.1.427/429 VOCs, also identified multiple isolates
31	of a newly emerging multiply-mutated B.1.526.1 variant that is now rapidly increasing in
32	the Eastern US. PCR approaches can be easily adopted in clinical laboratories, provide
33	rapid screening methods to allow early detection of newly emergent variants and to
34	efficiently triage cases for full genomic sequencing.

36 Introduction

The novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has 37 evolved considerably in the last six months. Most mutations of interest occur in the 38 Spike (S) protein, the viral protein that binds to the Angiotensin Converting Enzyme 2 39 (ACE2) cell receptor to initiate the attachment of the virus. Beginning in late 2020, 40 several biologically significant S mutations were shown to be associated with increased 41 transmissibility and virulence, diminished protection by antibodies from convalescent or 42 vaccinated anti-sera as well as decreased response to monoclonal antibody treatment. 43 Therefore, strategies to cost-effectively monitor for shifts in SARS-CoV-2 variants are 44 needed. 45

46 Three variants of concern (VOCs) with multiple mutations in the S gene have been identified as particularly concerning. The B.1.1.7 (501Y, V1) variant emerged in England 47 and rapidly became the dominant variant in the UK and has now spread to more than 48 49 50 countries [1]. B.1.1.7 contains 8-13 different S mutations, including, N501Y in the receptor binding domain (RBD). Studies suggested that it may be associated with 50 higher transmissibility and increased virulence [2, 3]. The B.1.3.5.1 (510Y. V2) variant 51 was first reported in late 2020 in South Africa [4] and variant P.1 (20J/501Y.V3) arose in 52 53 November 2020 in Brazil. The three spike mutations (K417N/T, E484K and N501Y) carried by both the Brazil and South African variants are associated with increased 54 binding to the human ACE 2 receptor, are more transmissible and mediate partial 55 escape from the protective humoral immunity resulting from prior infection or 56 57 vaccination [5-7].

58 In March 2021, the US Centers for Disease Control and Prevention (CDC) included B.1.427/B.1.429 as an additional VOC due to its rapid rise in incidence, and introduced 59 the "variant of interest" (VOI) category to encompass strain mutations that might 60 override neutralizing antibody responses, principally S E474K [8, 9]. B.1.427/B.1.429 61 carries the S L452R mutation which appears linked to the increased transmissibility of 62 63 this strain [10]. S L452R may be associated with reduction in neutralization using convalescent, post-vaccination sera and resistance to the neutralization by some 64 monoclonal antibodies that have acquired emergency use authorization for treatment 65 [10-12]. 66

67 The emergence of these VOC highlights that enhanced surveillance is urgently needed. Real time identification of both VOC and VOI will have significant impact not only on 68 management of this on-going pandemic but also patient care. However, this is not 69 70 possible without local sequencing capacity, which is not always available or may be limited in throughput capacity; WGS is also costly and takes considerable time to 71 complete. An accurate screening strategy would allow the selective use of WGS by 72 targeting samples of interest. This would maximize the use of WGS and broaden the 73 clinical laboratories able to actively participate in identification of VOC. 74

Here, we developed reverse-transcriptase real time PCR (rt-PCR) based assays to
screen for spike protein deletions 69-70, 242-244 and mutations N501Y, E484K and
L452R in clinical samples known to be positive for SARS-CoV-2. The pattern of
positivity accurately typed each VOC (as confirmed by genomic sequencing) except for
B.1.427/429 where the majority of cases detected (in March-April 2021) corresponded
to a newly emerging multiple mutated variant (previously types as B.1.526.1).

81 Materials and Methods

82 Study Samples

83 Nasopharyngeal swab samples were collected from pediatric patients and employees of Nationwide Children's Hospital, Columbus, Ohio. A flocked NP swab was used and 84 placed into viral transport media for transport to the laboratory for testing by a SARS-85 CoV2 PCR assay. This surveillance study utilized residual sample for assay validation 86 and was thus exempt human subject research. The set comprised 247 samples, 87 including 156 SARS-CoV-2 positive swabs from February 2nd to April 1st 2021 that 88 included all adequate samples with Ct values less than 35, and 91 samples collected 89 from Jan 1st 2021 to Feb 1st 2021 with Ct values less than 35 that were randomly 90

91 selected from adequate residual samples.

92 Diagnostic SARS-CoV-2 PCR Assay

93 We utilized a laboratory-developed modification of the CDC SARS-CoV-2 rt-PCR assay

which received Emergency Use Authorization by the FDA on April 17, 2020.

95 (https://www.fda.gov/media/137424/download; accessed March 24, 2021) Briefly, total

nucleic acid was obtained by extraction using the NucliSENS easyMag platform

97 (bioMerieux, Durham, NC) and 5µL of the eluate was added to a 25 µL total volume

reaction mixture [5µl of 1XTaqPath 1-Step RT-qPCR Master Mix, CG (Thermo Fisher

99 Scientific, Waltham, MA), 1.5 µl of RT-PCR primer/probe set (N1 or N2, 2019-nCoV kit,

100 Integrated DNA Technologies, Coralville, IA) and 13.5µl nuclease-free water]. The RT-

101 PCR was carried out using the Applied Biosystems[™] QuantStudio[™] 7 Flex Real Time

102 PCR detection system with QuantStudio[™] Real-Time PCR software v.1.3 (Thermo

103	Fisher Scientific, Waltham, MA) with the following running conditions: 25°C for 2min,
104	50°C for 15 minutes, enzyme activation at 95°C for 2min, and 45 cycles of 95°C for 3
105	sec and 55°C for 30 sec.

106 Mutation Screening Assays

SARS-CoV-2 positive sample were screened by four multiplex rt-PCR assays, with
 results available same day.

109 The sequences for detection of $\Delta 69-70$ were adapted from a multiplex real-time RT-

110 PCR assay for detection of SARS-CoV-2[13]. The probe overlaps with the sequences

that encode amino acids 69-70, therefore, a negative result for this assay predicts the

presence of a detection S 69-70 in the sample. Using a similar strategy, a primer/probe

set that targets the detection S Δ 242-244 was designed and was run in the same

reaction with S Δ 69-70. In addition, three separate assays were designed to detect

spike mutations 501Y, 484K and 452R and wild types 501N, 484E and 452L. The

sequences for each oligonucleotide are presented in Table 1.

Briefly, 5µL of the total nucleic acid eluate was added to a 20 µL total volume reaction

118 mixture [1XTaqPath 1-Step RT-qPCR Master Mix, CG (Thermo Fisher Scientific,

119 Waltham, MA), 0.9µM of each primer and 0.2µM of each probe]. The RT-PCR was

carried out using the ABI 7500 thermocycler (Life Technologies, Grand Island, NY). The

121 N501Y, E484K and L452R assays were carried out with the following running conditions:

122 25°C for 2 min, then 50°C for 15 min, followed by 10 min at 95°C, 45 cycles of 95°C for

123 15s and 65°C for 1 min. The Δ 69-70/ Δ 242-244 assay was run under the following

conditions: 25°C for 2 min, then 50°C for 15 min, followed by 10 min at 95°C, 45 cycles
of 95°C for 15s and 60°C for 1 min.

Samples that yielded negative result(s) in $\Delta 69-70/\Delta 242-244$ assay or were positive for

- 127 501YP2, 484KP2 and L452RP2 were considered screen-positive and assigned to a
- 128 VOC based on the scoring in Table 2. All screening positive samples and a similar
- number of screening negative samples collected in the same period were sent for WGS.
- 130 SARS-CoV-2 Whole Genome Sequencing

131 Previously extracted RNA underwent 1st and 2nd strand cDNA synthesis (NEBNext®

132 Ultra# II Non-Directional RNA Second Strand Synthesis Module, NEB, Ipswich, MA)

followed by sequencing using two different clinically validated amplicon-based methods.

134 Most samples were analyzed using the SARS-CoV-2 Research Panel primers

135 (ThermoFisher) on the Ion Chef-S5 sequencer (ThermoFisher) per manufacturer's

136 conditions. The remaining sequences were analyzed using the CovidSeq kit (Illumina,

137 San Diego, CA) per manufacturer's conditions and sequenced on the NextSeq 550

138 sequencer (Illumina). Strain typing on the two different assays were cross-validated

using a set of 20 SARS-CoV-2 positive and 5 SARS-CoV-2 negative samples.

140 Genomic Analyses and Strain Typing

Sequence analysis tools include custom pipelines utilizing GATK and Mutect2
(Broad Institute) and Dragen SARS-COVID variant detection (for CovidSeq assay).
Adequate sequencing required coverage of strain-distinguishing areas of the ORF1a, S,
N and ORF8 genes at least 100X depth. All but two sequences in this series yielded
adequate strain-typable sequences and no sample contained a mixed population of

viruses. Viral sequences were strain-typed using Pangolin (https://cov-lineages.org) and 146 NextStrain criteria (https://nextstrain.org/blog/2021-01-06-updated-SARS-CoV-2-clade-147 naming). Novel combinations of mutations were investigated for similar viruses using 148 the laboratory internal sequence database (1110 sequences as of 4/1/21) and/or the 149 GISAID database (accessed at gisaid.org). 150 Results 151 **Correlation of RT-PCR Mutation Screen Results with Whole Genome SARS-CoV-2** 152 153 Sequencing From Jan 2021 to April 1st, we screened 247 samples for VOC and VOI. Among all 154 screened samples, 128 samples were collected from hospital employees, 91 samples 155 156 were from outpatients and 28 samples were from hospitalized or emergency room 157 patients. A total of 102 samples were sent for WGS. 158 There were 61 screen-positive samples and 41 screen-negative samples sent for WGS. The screening assays were 100% concordant with the WGS for identification of the 159 three RBD mutation (Table 3). The screening assays successfully predicted the 160 presence of all 25 B.1.1.7 and 5 P.1 VOCs (Table 4). Six samples were positive for only 161 the E484K mutation, with five confirmed to be P.2 and one confirmed to be R.1 by 162 WGS. The screening PCR assays had 100% negative agreement when compared to 163 WGS for prediction of these VOCs and VOIs. Sixteen of the samples were positive only 164 for N501Y and were shown by sequencing to be the 20G/501Y strain we have 165 166 previously described [14] in fourteen and B.1.1.165 in two. Eight samples were screen-

167	positive for S L452R	with 3 of them stra	in typed as B.1.427/E	3.1.429, and five
			21	,

- representing the newly emerging B.1.526.1 variant described in more detail below.
- All negative screening samples were negative for VOC or VOI by WGS. Forty one
- screen-negative samples were found to be commonly encountered B.1 or B.1.2 with no
- 171 S mutations of concern. No sample was positive only for S deletion Δ 69-70 or S deletion
- 172 Δ 242-244. One sample that had suboptimal amplification in the Δ 69-70 assay was
- found to have a mutation in the primer binding site.

174 Timing of Emergence of PCR-detected Variants of Concern Matches Results from

- 175 From January to April 1st 2021, we screened 247 SARS-CoV-2 samples. As shown in
- Figure 1, the earliest case with B.1.1.7 was identified in mid-February 2021,
- subsequently, cases of B.1.1.7 were found in every batch of samples tested. The
- earliest case with P.1 was also collected in mid-February 2021, with a substantial
- increase in P.1 positive cases over time. The first B.1.429 in our population appeared in
- 180 late March 2021.

In the third week of February, 2021, one sample collected from a patient was found to carry both N501Y and E484K mutations and was sent for WGS. The sequences of this sample closely relate to Brazil P.1. VOC and was designated into lineage B.1.1.28 and was the first P.1. sample reported in the state of Ohio (EPI_ISL_1164183). In the same week, another sample collected from an employee was found to carry Δ 69-70 and E484K mutation that represent the first Ohio sample of the emerging B.1.525 lineage (EPI_ISL_1203843).

188 Three of the L452R-bearing viruses in our screen were documented to be B.1.427/429.

- 189 This VOC first appeared in California in July 2020 (EPI_ISL_765997) and is
- characterized by Spike mutations S13I, W152C as well as L452R. In early November
- 191 2020, B.1.427/429 became the predominant strain in Southern California before
- spreading throughout the United States in December-January 2020. The observed
- increase in B.1.427/429 in our study matches that seen in CDC totals from WGS in Ohio.

194 Emergence of the B.1.526.1 L452R-containing variant

Unlike the other VOC in our study, we noted that a positive screen for L452R still 195 196 required sequencing to definitively strain type. This was due to the emergence in late March in our area of another L452R-bearing strain besides the B.1.427/429 VOC. Five 197 198 of 8 (62.5%) screen-positive L452R-containing viruses from March 2021 represented a 199 newly emerging strain that has been tentatively strain-typed as B.1.526.1 (Table 5). The diagnostic PCR Ct values are presented in Table 6. In addition to L452R, this strain 200 201 has four additional S mutations, D80G, F157S, T859N and D950H, which include both 202 N-terminal and stalk variants. It shares with B.1.427/429, the 20C/B.1 backbone as indicated by mutations ORF1 T265I, ORF1a A1679S, ORF1a L3201P, ORF1b P314L, 203 ORF3a Q57H and S D614G. 204

Based on the frequency of the Spike mutations in B.1.526.1 viruses reported in GISAID as of April 10 2021, the variant likely developed from a L452R-bearing B.1 strain, then acquired F157S, D80G and Y145del, followed by T859 and D950H. The few GISAID sequences that do not follow this pattern are reported as suboptimal quality studies. A small number (n=7) of B.1.526.1 viruses contain D80N/N81Y instead of D80G. The

earliest GISAID-reported instances of B.1.526.1 were two sequences from New York
City collected on 12/18/20 (EPI_ISL_794288 and EPI_ISL_794289), with all sequences
through 2/5/21 reported from New York City (mostly, Bronx county). Spread to 11 other
states (including Ohio) occurred in February and then throughout the United States in
March, 2021. Given that 578 of 2369 (24.4%) viruses typed as B.1.526.1 lineage in
GISAID do not contain any of the above Spike mutations, lineage classification may be
provisional.

- A comparison of the incidence of the B.1.427/429 and B.1.526.1 strains in GISAID
- during 2021 shows a declining proportion of the forms and increases in the latter in
- 219 March matching our observations in Columbus (Figure 2).

220 Discussion

221 We describe a multiplex, mutation-specific rt-PCR-based strategy to rapidly and reliably screen for SARS-CoV2 genetic variants in a clinical laboratory setting. These assays 222 223 detect all three target RBD spike mutations and have a 100% concordance with the 224 strains identified by WGS. Using simple rules based on the combination of assay results, 225 the strategy successfully identified all B.1.1.7 and P.1 samples, with the frequencies of each of the VOCs detected matching their emergence by the CDC and Department of 226 Health WGS surveillance studies over the last several months. Using this strategy, we 227 successfully identified and reported the first P.1 variant in Ohio from a patient which 228 229 suggested that the P.1 variant has already spread in the community; a finding confirmed 230 in subsequent reports.

231 However, for S L452R-positive screens, we noted that both B.1.427/429 VOC and a newly emerging B.1.526.1 strain were detected [15]. The latter samples were identified 232 only in the latest March 2021 samples and match the observed spread of GISAID-233 reported B.1.526.1 viruses outside of the state of New York. Although both of these 234 strains show multiple mutations in other areas of the Spike gene, the L452R mutation is 235 their only RBD mutation. This mutation has been associated with resistance to 236 neutralization by RBD-binding monoclonal antibodies, such as bamlanivimab [12], which 237 has affected the use of these therapies. The single RBD mutation in these two strains 238 239 is in contrast to other VOC which besides N501Y and E484K (in two of them, P.1 and B.1.351) show additional mutations known to alter receptor binding affinity [16-18]. It will 240 be important to monitor sequential samples from these strains to see if the acquire 241 additional RBD mutations, particularly at antibody escape residues, as B.1.1.7 viruses 242 have done in some cases. 243

Mutation-specific PCR assays can be run in real-time with a turn-around time of several 244 hours, which is significantly faster than WGS and in this configuration can be performed 245 cost-effectively on all PCR-positive samples. This broader approach is clearly superior 246 to the use of other VOC indicators such as S-gene dropout in the 3-target diagnostic 247 RT-PCR assay (TaqPath kit, Thermo Fisher Scientific, Waltham, MA) which has been 248 reported by others as a method to detect the H69-V70del associated with B.1.1.7 [9, 19-249 22] . Similarly, PCR-based N501Y and E484K mutation-specific assays are sensitive for 250 251 detection of P.1 and B.1.351 [23, 24], respectively, but will not definitively distinguish them as an increasing number of VOIs also bear these mutations. In this study, we 252 could not fully evaluate all scoring combinations, particularly the use of co-positivity for 253

N501Y and Δ242-244 as a marker for the B.1.351 VOC, as we did not find any
examples of this virus in our test population. However, the combination of assay
presented here has more diagnostic utility in distinguishing VOC and VOI than single
mutation-specific PCR approaches.

258 There are some limitations to a reflex mutant-PCR panel strategy. First, many

diagnostic PCR platforms can deplete swab material, leaving an inadequate volume of

residual sample for a multi-tube mutation screen. These assays also did not perform

well when the diagnostic PCR Ct value is greater than 35 cycles. However, this problem

is shared with amplicon-based WGS [25]. As demonstrated by our finding with L452R-

263 positives, new variants of SARS-CoV-2 are still emerging so confirmation of some

results by WGS will still be required. Finally, to evaluate for novel mutations, a sampling

of screen-negative specimens for WGS will be an important component of a full

surveillance strategy.

In summary, the use of a panel of multiplex, mutant-specific rt-PCR assays represents

an ideal balance of cost, turn-around-time and accuracy for detecting SARS-CoV-2

VOC and VOI. The technology is amenable for use in a larger number of clinical

laboratories than next-generation sequencing. In our current environment requiring

rapid strain typing to guide both treatment decisions and public health measures, such a

rapid and accessible approach will be essential.

273

274 Acknowledgments

- For the GIS sequences in Figure 2, we acknowledge the originating laboratories
- responsible for obtaining the specimens and the submitting laboratories where genetic
- sequence data were generated and shared via the GISAID Initiative.

278

280 **Reference**

- 281 1. Alpert, T., et al., Early introductions and community transmission of SARS-CoV-2 variant
- 282 B.1.1.7 in the United States. medRxiv, 2021.
- 283 2. Challen, R., et al., Risk of mortality in patients infected with SARS-CoV-2 variant of
- 284 *concern 202012/1: matched cohort study.* BMJ, 2021. **372**: p. n579.
- 285 3. Davies, N.G., et al., Increased mortality in community-tested cases of SARS-CoV-2 lineage
- 286 *B.1.1.7.* Nature, 2021.
- 4. Tegally, H., et al., Emergence of a SARS-CoV-2 variant of concern with mutations in spike
- 288 glycoprotein. Nature, 2021.
- Zucman, N., et al., Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A
 case report. Clin Infect Dis, 2021.
- 291 6. Moyo-Gwete, T., et al., SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing
- 292 *antibodies.* bioRxiv, 2021.
- 293 7. Garcia-Beltran, W.F., et al., *Circulating SARS-CoV-2 variants escape neutralization by*
- 294 *vaccine-induced humoral immunity.* medRxiv, 2021.
- 295 8. *Centers for Disease Control and Prevention*. 2021; Available from:
- 296 https://www.cdc.gov/coronavirus/2019-ncov/.
- 297 9. Annavajhala, M.K., et al., *A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in*298 *New York.* medRxiv, 2021.
- 299 10. Zhang, W., et al., Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA,
- 300 2021.

301	11.	Deng, X., et al., Transmission, infectivity, and antibody neutralization of an emerging
302		SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv, 2021
303	12.	Liu, Z., et al., Identification of SARS-CoV-2 spike mutations that attenuate monoclonal
304		and serum antibody neutralization. Cell Host Microbe, 2021. 29 (3): p. 477-488 e4.
305	13.	Zhen, W. and G.J. Berry, Development of a New Multiplex Real-Time RT-PCR Assay for
306		Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection. J Mol Diagn,
307		2020. 22 (12): p. 1367-1372.
308	14.	Tu H, A.M., Kubatko L, Hunt M, Pan X, Ru P, Garee J, Thomas K, Mohler P, Pancholi P,
309		Jones D. , Distinct Patterns of Emergence of SARS-CoV-2 Spike Variants including N501Y
310		in Clinical Samples in Columbus Ohio. bioRxiv, 2021.
311	15.	Greaney AJ, S.T., Barnes CO, Weisblum Y, Schmidt F, Caskey M, Gaebler C, Cho A,
312		Agudelo M, Finkin S, Wang Z, Mutational escape from the polyclonal antibody response
313		to SARS-CoV-2 infection is largely shaped by a single class of antibodies. bioRxiv, 2021.
314	16.	Starr, T.N., et al., Prospective mapping of viral mutations that escape antibodies used to
315		<i>treat COVID-19.</i> Science, 2021. 371 (6531): p. 850-854.
316	17.	Greaney, A.J., et al., Comprehensive mapping of mutations in the SARS-CoV-2 receptor-
317		binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host
318		Microbe, 2021. 29 (3): p. 463-476 e6.

- 319 18. Greaney, A.J., et al., Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-
- 320 Binding Domain that Escape Antibody Recognition. Cell Host Microbe, 2021. 29(1): p. 44-
- 321 57 e9.

322	19.	Bal, A., et al., Two-step strategy for the identification of SARS-CoV-2 variant of concern
323		202012/01 and other variants with spike deletion H69-V70, France, August to December
324		<i>2020</i> . Euro Surveill, 2021. 26 (3).
325	20.	Ibba, G., et al., A straightforward molecular strategy to retrospectively investigate the
326		<i>spread of SARS-CoV-2 VOC202012/01 B.1.1.7 variant.</i> J Infect Dev Ctries, 2021. 15 (2): p.
327		242-246.
328	21.	Gaymard, A., et al., Early assessment of diffusion and possible expansion of SARS-CoV-2
329		Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to
330		March 2021. Euro Surveill, 2021. 26 (9).
331	22.	Borges, V., et al., Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from
332		nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data,
333		Portugal, week 49 2020 to week 3 2021. Euro Surveill, 2021. 26 (10).
334	23.	Banada, P., et al., A Simple RT-PCR Melting temperature Assay to Rapidly Screen for
335		Widely Circulating SARS-CoV-2 Variants. medRxiv, 2021.
336	24.	Matic, N., et al., Rapid Detection of SARS-CoV-2 Variants of Concern, Including
337		B.1.1.28/P.1, in British Columbia, Canada. Emerg Infect Dis, 2021. 27(6).
338	25.	Charre, C., et al., Evaluation of NGS-based approaches for SARS-CoV-2 whole genome
339		characterisation. Virus Evol, 2020. 6(2): p. veaa075.

- 341 Figure Legends
- Figure 1. Shifts in the proportions of SARS-CoV-2 strains from January to March
 2021.
- Figure 2. Comparison of incidence in the United States of B.1.427/429 and
- 345 **B.1.526.1 in 2021.** Spike L452R-bearing SARS-CoV-2 genomes from North America
- were downloaded from GISAID and strain type confirmed by mutation pattern. Graphed
- is the proportion of B.1.427/429 versus B.1.526 viruses during each 2-week period in
- 348 2021.
- 349
- 350

Table 1: Mutation-specific reverse-transcriptase PCR: primers and probes.

Assays	Oligo name	Sequences
S gene Δ69-70/ Δ242-244	S Δ69-70 F	5'-TCAACTCAGGACTTGTTCTTAC-3'
multiplex assay	S Δ69-70 R	5'-TGGTAGGACAGGGTTATCAAAC-3'
	S Δ69-70 P	5'- FAM-TGGTCCCAGAGACATGTATAGCAT- BHQ1-3'
	S Δ242-244 F	5'- TGGTAGATTTGCCAATAGGTATTAACA -3'
	S Δ242-244 R	5'- CTGAAGAAGAATCACCAGGAGTCA -3'
	S Δ242-244 P	5' - VIC-ACTTTACTTGCTTTACATAGAAG-MGB -3'
S gene N501Y assay	S N501Y F	5'- TGTTACTTTCCTTTACAATCATATGGTTTC -3'
accay	S N501Y R	5'-GAAAGTACTACTACTCTGTATGGTTGGTAACC - 3'
	S 501N P1	5'-VIC-CAACCCACTaATGGTGTT-MGB-3'
	S 501Y P2	5'-FAM-CAACCCACTtATGGTGTT-MGB3'
S gene E484K assav	S E484K F	5'-CAGGCCGGTAGCACACCTT-3'
uoouy	S E484K R	5'-GTTGGAAACCATATGATTGTAAAGGA-3'
	S 484E P1	5'-FAM-TAATGGTGTTgAAGGTTT -3'
	S 484K P2	5'-VIC-TGTAATGGTGTTaAAGGT -3'
S gene L452R assav	S L452R F	5'-TGATAGATTTCAGTTGAAATATCTCTCTCA-3'
	S L452R R	5'-AATCTTGATTCTAAGGTTGGTGGTAATTAT-3'
	S 452L P1	5' FAM-CCTAAACAATCTATACaGGTAA-MGB-3'
	S 452R P2	5'-VIC-CTAAACAATCTATACcGGTAAT-MGB-3'

352

Table 2: Strain-typing rules for interpretation of screening results.

	Mutations						
	Δ69-70	Δ242-244	N501Y	E484K	L452R		
Variants of Concern							
B.1.1.7	Pos	Neg	Pos	Neg	Neg		
B.1.351	Neg	Pos	Pos	Pos	Neg		
P.1	Neg	Neg	Pos	Pos	Neg		
B.1.427/ B. 1.429 or B.1 80G-157L-4	Neg	Neg	Neg	Neg	Pos		
Variants of Interest							
B.1.525	Pos	Neg	Neg	Pos	Neg		
R.1, P.2, B.1.525, B.1.526,	Neg	Neg	Neg	Pos	Neg		
B.1.2/501Y or B.1.1.165	Neg	Neg	Pos	Neg	Neg		

Table 3: Performance of the Screening Assays for Detection of RBD Mutations.

		WGS n	=102				
		L452R		E484K		N501Y	
		Pos	Neg	Pos	Neg	Pos	Neg
Screening	Pos	8	0	12	0	46	0
assays	Neg	0	94	0	90	0	56
PPA %		100		100		100	
NPA %		100		100		100	

³⁵⁷

7 PPA: positive percentage agreement; NPA: negative percentage agreement

Table 4: Performance of the screening assays for detection of variants.

		WGS	n=102												
Variants of Concern								Variants of Interest							
		B.1.1.7		B.1.351 P.1		-	B.1.427 or B.1.429		B.1.525		P.2, B.1.526 or R.1		20G/501Y as in Ref 14 or B.1.1.165		
		Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg
Screening	Pos	25	0	0	0	5	0	3	5 ^{\$}	1	0	6*	0	16	0
assays	Neg	0	77	0	102	0	97	0	94	0	101	0	96	0	86
PPA %		100 N/A		100		37.5	37.5		100		100		100		
NPA %		100		100		100		100	100 100			100		100	

361 \$All five samples were identified carrying a newly emerged variant: B.1.526.1

³⁶² *Five samples were identified as strain P.2 and one sample was strain R.1

363 PPA: positive percentage agreement; NPA: negative percentage agreement

364

Table 5: Spike mutations associated with a newly emerged S L452R-containing variant.

Amino acid change	cDNA location	# GISAID*	# B.1.526.1 viruses (%)	Domain	Other lineages commonly showing the mutation
p.Asp80Gly	c.239A>G	587	548 (93.4)	NTD	
p.Phe157Ser	c.470T>C	661	588 (89.0)	NTD	
p.Leu452Arg	c.1355T>G	12,997	608 (4.7)	RBD	B.1.427/429, A.2.5
c.2576C>A	p.Thr859Asn	840	461 (54.9)	CR	B.1.36.9
p.Asp950His	c.2848G>C	459	419 (91.3)	HR1	
4 or 5 of thse S mutations		449	449 (100)		

367 Abbrevisions: NTD, N-terminal domain; RBD, receptor binding domain; HR1, heptad repeat 1;

- 368 CR: connecting region.
- 369 *Data as of 4/10/21

Table 6: Ct values of the samples carry newly emerged S L452R-containing

variant.

B.1.526.1 Samples	Ct Values				
	N1	N2			
Patient 1	31.8	33.3			
Patient 2	23.2	23.5			
Employee 1	13.6	12.5			
Patient 3	29.2	28.8			
Patient 4	23.4	24.2			



Figure 1. Shifts in the proportions of SARS-CoV-2 strains from January to March

2021.



379

380 Figure 2. Comparison of incidence in the United States of B.1.427/429 and

381 **B.1.526.1 in 2021.**

- 382 Spike L452R-bearing SARS-CoV-2 genomes from North America were downloaded
- from GISAID and strain type confirmed by mutation pattern. Graphed is the proportion
- of B.1.427/429 versus B.1.526 viruses during each 2-week period in 2021.